TY - JOUR
T1 - Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)
AU - Grosset, Jacques H.
AU - Ammerman, Nicole C.
PY - 2013/7
Y1 - 2013/7
N2 - Evaluation of: Diacon AH, Dawson R, Von Groote-Bidlingmaier F et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 57(5), 2199-2203 (2013). During the past decade considerable efforts have been made to develop and register new anti-TB drugs, making them available for patients in need. Bedaquiline (BDQ), approved by the US FDA in December 2012, is the first new anti-TB drug available for treatment of this disease since rifampicin became available in 1967. BDQ has the peculiarity of being a drug with a very long half-life and potent antimicrobial activity that becomes noticeable only after the first 4 days of treatment. Consequently, Diacon et al. have conducted a 14-day dose-ranging study aimed at assessing the early bactericidal activity of BDQ in TB patients who received loading doses of the drug during the first 2 days of treatment. The loading doses partially overcame the delayed antimicrobial activity only in patients treated daily with as much as 400 mg.
AB - Evaluation of: Diacon AH, Dawson R, Von Groote-Bidlingmaier F et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 57(5), 2199-2203 (2013). During the past decade considerable efforts have been made to develop and register new anti-TB drugs, making them available for patients in need. Bedaquiline (BDQ), approved by the US FDA in December 2012, is the first new anti-TB drug available for treatment of this disease since rifampicin became available in 1967. BDQ has the peculiarity of being a drug with a very long half-life and potent antimicrobial activity that becomes noticeable only after the first 4 days of treatment. Consequently, Diacon et al. have conducted a 14-day dose-ranging study aimed at assessing the early bactericidal activity of BDQ in TB patients who received loading doses of the drug during the first 2 days of treatment. The loading doses partially overcame the delayed antimicrobial activity only in patients treated daily with as much as 400 mg.
KW - tuberculosis treatment
UR - http://www.scopus.com/inward/record.url?scp=84880865942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880865942&partnerID=8YFLogxK
U2 - 10.1586/14787210.2013.811848
DO - 10.1586/14787210.2013.811848
M3 - Review article
C2 - 23879605
AN - SCOPUS:84880865942
SN - 1478-7210
VL - 11
SP - 649
EP - 651
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 7
ER -